Pancreatic in Medical Technology

TNFerade(TM) Phase III Data Presented at ASCO

... -- Overall survival data in locally advanced pancreatic cancer patients treated with TNFerade(TM) in GenVec's ongoing Phase III pancreatic Cancer Clinical Trial with TNFerade(TM) (PACT) ... Chemoradiation in Patients with Locally Advanced pancreatic Cancer: Interim Analysis of Overall Survival," ...

Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer

... (165), ovarian (143), stomach (98), rectal (87), pancreatic (53), head and neck (36), and other cancers (54) ... 8.8 percent in the placebo arm). Patients with pancreatic cancer also experienced a high overall rate of ... higher incidence of events in lung and pancreatic cancer patients, further studies should focus on ...

Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483

... inhibits tumor growth in an animal model of pancreatic cancer. In previous animal studies, the company ... studies have shown that approximately 90% of pancreatic cancers express tissue factor. Accordingly, we ... to evaluate PCI-27483's effects in patients with pancreatic cancer." About Factor VII and PCI-27483 ...

ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer

... november is pancreatic Cancer Awareness Month Oak Brook, Ill., ... for Gastrointestinal Endoscopy (ASGE) and the pancreatic Cancer Action Network are teaming up this November to raise awareness about pancreatic cancer, educating patients about the disease and ...

New Cancer Treatment Shrinks Pancreatic Tumor

... is realizing outstanding results against pancreatic cancer. Following five weeks of treatment, a ... longer could be definitely identified on scans. pancreatic cancer usually is fatal six to nine months after ... this kind of response is virtually unheard of in pancreatic cancer. At the very least, we're looking at ...

RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors

... - 82% of patients with pancreatic neuroendocrine tumors (NET) experienced clinical ... Depot - 77% of patients with pancreatic NET experienced clinical benefit when ... to become new treatment for patients with pancreatic NET who currently have limited ...

Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer

... of brain cancers have activity against human pancreatic cancers in a mouse model. Dr. John S. Kovach, ... significant activity against human pancreatic cancer cells growing in mice. These are early ... evidence that these drugs are able to eliminate pancreatic cancers but rather slow their growth. We are ...

PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity

... CF-related lung infection and also had CF-induced pancreatic insufficiency. Results from the study showed that ... disease, pathological lung infection, and pancreatic insufficiency. Statistically significant ... the majority of cystic fibrosis patients take pancreatic enzyme supplements to assist with food ...

Anti-TGF-Beta Antisense AP 12009 Shows Very Good Safety and Tolerability in Systemic Treatment of Pancreatic Carcinoma, Malignant Melanoma and Colorectal Carcinoma

... tolerability in the systemic treatment of pancreatic carcinoma, malignant melanoma and colorectal ... Phase I/II study patients with advanced stage pancreatic carcinoma, malignant melanoma or colorectal ... AP 12009 treatment. Another patient with stage IV pancreatic carcinoma and several liver metastases had ...

Patients with Pancreatic Cancer Can Benefit From Avastin(R) Plus Tarceva(R)

... the time patients with metastatic pancreatic cancer live without their disease getting worse ... a trend towards extending life expectancy. pancreatic cancer is the sixth leading cause of cancer death ... disease. "For patients with advanced pancreatic cancer, the treatment options are limited," ...

Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer

... of an on-going Phase I/II study of Rexin-G for pancreatic cancer confirmed Rexin-G's anti-tumor activity ... patients with metastatic chemotherapy-resistant pancreatic cancer. The clinical trial design includes 5 ... I/II clinical trials using Rexin-G in sarcoma, pancreatic cancer, and breast cancer, and a Phase II study ...

Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging

... the urgent need for a safe procedure to assess pancreatic abnormalities," stated Walter C. Herlihy, ... MRI to improve the ability to detect pancreatic duct abnormalities relative to MRI alone. Detailed visual assessment of the pancreatic ducts is important in the assessment, diagnosis ...

Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging

... human secretin, to improve the assessment of pancreatic duct structures by magnetic resonance imaging ... MRI to improve the ability to detect pancreatic duct abnormalities relative to MRI alone. Detailed visual assessment of the pancreatic ducts is important in the assessment, diagnosis ...

Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer

... in the treatment of patients with metastatic pancreatic cancer. The Phase 2 pancreatic Cancer Study will be conducted at ... the clinical trials consortium, the pancreatic Cancer Research Team. More information regarding ...

Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas

... tract (adenocarcinomas of gastroesophageal, pancreatic and colorectal origin). RAV12, Raven's lead ... the treatment of patients with metastatic pancreatic cancer. An additional Phase 2 study employing ... More than 90 percent of colon, stomach and pancreatic tumor specimens express the RAV12 defined ...

Mayo Clinic Study Finds Further Association Between Diabetes and Pancreatic Cancer

... A new Mayo Clinic study found that 40 percent of pancreatic cancer patients are diagnosed with diabetes prior to their pancreatic cancer diagnosis. The onset of diabetes appears ... an important clue for earlier detection of pancreatic cancer. The study was published in this month's ...

Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.

... and may have the potential to improve pancreatic beta-cell function. The NDA submission was ... secretion. In addition, GLP-1 suppresses pancreatic glucagon secretion and subsequent liver glucose ... deficiency and have the potential to improve pancreatic beta-cell function. About Takeda's Commitment ...

EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer

... trial with MKC-1 in patients with advanced pancreatic cancer. The primary objectives of this study will ... MKC-1 in unresectable or metastatic pancreatic cancer patients who have failed at least one ... tolerability and overall median survival time of pancreatic cancer patients treated with MKC-1. Massachusetts ...

Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference

... - - Preliminary evidence of activity in pancreatic cancer - - Phase II portion of the clinical trial in pancreatic cancer patients has ... Importantly, of the four evaluable patients with pancreatic cancer, there was one PR and three SD, which ...

BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor

... data demonstrating that BSI-401 inhibited pancreatic cancer cell growth in vitro and in vivo, both ... enough to act as a targeted monotherapy." pancreatic cancer kills more than 30,000 each year in the United States. Patients with advanced pancreatic cancer do not usually survive a year after ...

Tapestry Initiates Phase 2 Trial of TPI 287 for the Treatment of Advanced Pancreatic Cancer

... study of TPI 287 in patients with advanced pancreatic cancer. This is the second Phase 2 trial ... "Currently available taxanes are not approved for pancreatic cancer and effective treatment options for this ... officer of Tapestry Pharmaceuticals. "This pancreatic trial, combined with our experience in both the ...

Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference (ECCO)

... with gemcitabine for the treatment of advanced pancreatic cancer, six-month and one-year survival were 50% ... should have a role in the treatment of pancreatic cancer and, taken together with our Phase 3 ... may benefit patients with chemotherapy nave pancreatic adenocarcinoma. Hematologic and renal toxicity ...

Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO)

... take place: Glufosfamide (GLU) in metastatic pancreatic adenocarcinoma previously treated with ... Phase 2 glufosfamide plus gemcitabine front-line pancreatic cancer trial was 21% (including one unconfirmed ... Glufosfamide (GLU) plus gemcitabine (GEM) in pancreatic adenocarcinoma: Results of a Phase 2 trial. ...

Stand Up To Cancer Awards $73.6 Million for Novel, Groundbreaking Cancer Research

... "Cutting off the Fuel Supply: A New Approach to the Treatment of pancreatic Cancer" / Leaders: Craig B. Thompson, M.D., Director, Abramson Cancer ... further development of proposals, where needed, and in two instances (in pancreatic cancer and breast cancer) where two teams proposed related approaches to ...

PTC Announces Data Showing That PTC124 Causes Statistically Significant Improvements in Chloride Channel Function in Cystic Fibrosis Patients

... had nonsense-mutation CF, pathological lung infection, and CF-induced pancreatic insufficiency. In a cross-over design testing 14 days of PTC124 at two ... lung function. In addition, the majority of cystic fibrosis patients take pancreatic enzyme supplements to assist with food absorption in digestion. There is a ...

Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes

... role in regulating blood glucose levels and have the potential to improve pancreatic beta-cell function. GLP-1 and GIP are produced by the digestive tract in ... glucose-dependent insulin secretion. In addition, GLP-1 suppresses pancreatic glucagon secretion and subsequent liver glucose production, enhances ...

Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer

... 2 clinical trials for multiple indications, including prostate cancer, pancreatic cancer, and leukemia. The company is currently manufacturing GVAX ... for prostate cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus ...

Interim Analysis Supports Continuation of Cell Genesys' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer

... 2 clinical trials for multiple indications, including prostate cancer, pancreatic cancer, and leukemia. The company is currently manufacturing GVAX ... for prostate cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus ...

Raven Announces Continued Enrollment of Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas

... of the gastrointestinal tract (adenocarcinomas of gastroesophageal, pancreatic and colorectal origin). RAV12, Raven's lead clinical monoclonal antibody ... after metastatic spread. More than 90 percent of colon, stomach and pancreatic tumor specimens express the RAV12 defined antigen, RAAG12. Adenocarcinomas ...

Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas

... with time to progression exceeding 8 months and one patient with advanced pancreatic cancer had a > 50% reduction in the relevant tumor marker, CA19-9 and ... after metastatic spread. More than 90 percent of colon, stomach and pancreatic tumor specimens express the RAV12 defined antigen, RAAG12. Adenocarcinomas ...

Tapestry Pharmaceuticals Presents Data on TPI 287 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

... when delivered orally in subcutaneous mouse xenograft models of both pancreatic cancer and glioblastoma multiforme (GBM). Tapestry has Phase 2 studies underway for TPI 287 in pancreatic and prostate cancer. The Company plans to evaluate TPI 287 in a Phase 2 ...

Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer

... treatment of patients with locally advanced or metastatic NSCLC. pancreatic Cancer The treatment of patients with locally advanced or ... by a one week rest period. This four week cycle is then repeated. pancreatic Cancer The recommended dose of gemcitabine is 1,000mg/m(squared), given ...

Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes

... drug that has demonstrated excellent glucose control and improved pancreatic function through a dual mechanism of action in insulin-resistant animal ... glucagon-like peptide, or GLP-1, which is a hormone that helps to preserve pancreatic function, thereby enhancing insulin secretion. ABOUT ISIS ...

MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus

... Dr. Hering is evaluating the use of teplizumab as an induction therapy in pancreatic islet cell transplantation. Additional information regarding the studies ... diabetes mellitus within 4-12 months of diagnosis pancreatic Led by Dr. Bernhard http://www.clinicaltrials.gov islet ...

Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership

... partnership between JDRF and GNF aims to deliver a succession of drug candidates to the clinic over the next four years. The initial focus will be on pancreatic beta cell regeneration and survival, to restore beta cell function in diabetes. The program builds on current JDRF funding at GNF that has resulted ...

Study Suggests Vitamin D Screening and Appropriate Supplementation Indicated for All Cancer Patients

... age at presentation was 55.7 years (SD = 10.2) and the most common cancer types were lung (133, 18%), breast (131, 17.8%), colorectal (97, 13.2%), pancreatic (86, 11.7%), prostate (44, 6%) and ovarian (38, 5.2%). Before the study, the researchers hypothesized that malnutrition could contribute to ...

Researchers Say More Aggressive Vitamin D Supplementation Needed in Obese Cancer Patients

... (SD = 10.2). The mean BMI was 27.9 kg/m2 (SD = 6.7). The most common cancers were lung (134, 18.1%), breast (131, 17.7%), colorectal (97, 13.1%), pancreatic (86, 11.6%), prostate (45, 6.1%) and ovarian (39, 5.3%). The mean vitamin D (serum 25(OH)D) was 21.9 ng/ml (SD = 13.5). The study concluded that ...

Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines

... heart attack and stroke) was statistically significant. RECORD showed no evidence of an increase in malignancies. There were fewer events of pancreatic cancer in patients taking Avandia although the numbers were small. "RECORD provides important and reassuring information about Avandia for ...

Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer

... are being developed for the treatment of rheumatoid arthritis, multiple sclerosis and other autoimmune diseases as well as for the treatment of pancreatic and metastatic breast cancer. Plexxikon's proprietary Scaffold-Based Drug Discovery(TM) platform integrates multiple state-of-the-art ...

BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting

... data generated to date, coupled with a benign side effect profile. Previous clinical trials have enrolled patients with breast cancer, melanoma, and pancreatic cancer in addition to head and neck cancer, and clinical activity has been observed in each of these cancer types. The Company recently commenced a ...